An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers
Latest Information Update: 27 Apr 2026
At a glance
- Drugs DA 5230 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
Most Recent Events
- 27 Apr 2026 New trial record